Disease · MONDO_0004970
adenocarcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. adenocarcinoma. Diseases, record MONDO_0004970. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004970
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- adenocarcinoma NOS (morphologic abnormality), adenocarcinoma, malignant, adenocarcinoma, no subtype (morphologic abnormality), adenocarcinomas
- Open Targets
- Highest stage of its drugs
- Approval, for 6 of its 89 drugs, from DailyMed and EMA Human Drugs
- Open Targets
Drugs89
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FLUOROURACIL | CHEMBL185 | Small molecule | Approval | DailyMed | 21 | 20 | 19 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Approval | EMA Human Drugs | 20 | 13 | 13 | Drugs and targets |
| IRINOTECAN HYDROCHLORIDE | CHEMBL3989514 | Small molecule | Approval | DailyMed | 3 | 2 | 1 | Drugs and targets |
| THIOTEPA | CHEMBL671 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| MITOMYCIN | CHEMBL105 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| PEMETREXED TROMETHAMINE | CHEMBL3989962 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 23 | 23 | 23 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 3 | ClinicalTrials.gov | 14 | 14 | 14 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| PEMETREXED | CHEMBL225072 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
1 to 10 of 89
See all 89 drugsTargets192
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 7 | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 7 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 4 | Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 4 | Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 4 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 3 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor | 3 | Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2260 | Drugs and targets |
| FGFR2 | Fibroblast growth factor receptor | 3 | Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2263 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 3 | Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5156 | Drugs and targets |
1 to 10 of 192
See all 192 targetsTrials95
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00805194 | LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer | Phase 3 | 1,314 | 2014-12-01 | Carcinoma, Non-Small-Cell Lung | DOCETAXEL, NINTEDANIB | Its record names the disease | ClinicalTrials.gov |
| NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | Phase 2 | 529 | 2024-06-14 | Cancer of Unknown Primary Site | ALECTINIB, ATEZOLIZUMAB, BEVACIZUMAB, COBIMETINIB, ENTRECTINIB, ERLOTINIB, GEMCITABINE, IPATASERTIB, IVOSIDENIB, OLAPARIB, PACLITAXEL, PEMIGATINIB, PERTUZUMAB, TRASTUZUMAB, VEMURAFENIB, VISMODEGIB | Its record names the disease | ClinicalTrials.gov |
| NCT00004547 | Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy | Phase 2 | 188 | 2011-11-22 | Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm | CISPLATIN, FLUOROURACIL, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00560560 | Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments | Phase 2 | 168 | 2013-05-09 | Colorectal Neoplasm | FIGITUMUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02387216 | A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC | Phase 2 | 153 | 2021-10-12 | Non-Small Cell Lung Cancer, NSCLC, Adenocarcinoma, Heregulin | DOCETAXEL, SERIBANTUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer | Phase 2 | 137 | 2014-05-16 | Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma | CISPLATIN, FLUOROURACIL, PACLITAXEL | Its record names the disease | ClinicalTrials.gov |
| NCT00567359 | Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR | Phase 2 | 100 | 2018-12-11 | Non-small Cell Lung Cancer | ERLOTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00445848 | S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer | Phase 2 | 89 | 2016-09-07 | Lung Cancer | BEVACIZUMAB, ERLOTINIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03267940 | Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma | Phase 1 | 85 | 2020-02-07 | Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Gallbladder Adenocarcinoma | ATEZOLIZUMAB, CISPLATIN, GEMCITABINE, PEGVORHYALURONIDASE ALFA | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00215644 | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer | Phase 2 | 72 | 2018-11-02 | Esophageal Cancer, Gastric Cancer | CAPECITABINE, CISPLATIN, EPIRUBICIN, MATUZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 95
See all 95 trialsComparisons in its trials20
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: deaths from any cause | 107 of 652 | 77 of 655 | 1,307 | NCT00805194 | Trial comparisons |
| Nintedanib Plus Docetaxel vs Placebo Plus Docetaxel: serious adverse events | 224 of 652 | 206 of 655 | 1,307 | NCT00805194 | Trial comparisons |
| Figitumumab 20 mg/kg vs Figitumumab 30 mg/kg: serious adverse events | 56 of 85 | 53 of 83 | 168 | NCT00560560 | Trial comparisons |
| Arm A (Experimental): MM-121 in Combination With Docetaxel vs Arm B (Comparator): Docetaxel Alone: deaths from any cause | 64 of 103 | 25 of 49 | 152 | NCT02387216 | Trial comparisons |
| Arm A (Experimental): MM-121 in Combination With Docetaxel vs Arm B (Comparator): Docetaxel Alone: serious adverse events | 40 of 103 | 15 of 49 | 152 | NCT02387216 | Trial comparisons |
| Group 1 vs Group 2: serious adverse events | 30 of 72 | 20 of 65 | 137 | NCT00573131 | Trial comparisons |
| Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab vs ECX Only: serious adverse events | 0 of 35 | 0 of 36 | 71 | NCT00215644 | Trial comparisons |
| Arm A vs Arm B: deaths from any cause | 4 of 19 | 2 of 17 | 36 | NCT03738228 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 6 of 19 | 7 of 17 | 36 | NCT03738228 | Trial comparisons |
| Run-in Portion: PEGCISGEM vs Run-in Portion: PEGCISGEMATEZO: Run-in Portion: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters (Hematology and Blood Chemistry) | 0 of 9 | 0 of 9 | 18 | NCT03267940 | Trial comparisons |
1 to 10 of 20
See all 20 comparisons in its trialsPapers from its trials74
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004970
GET https://conductscience.org/api/diseases/v1/MONDO_0004970/drugs?page=2